hotspot -WSS

hotspot

author：Wikipedia 2025-10-02 00:53:05 - browse：56

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of independent advisers to the Food and Drug Administration voted overwhelmingly against a polarizing potential treatment for ALS on Wednesday, concluding that the medicine’s messy supporting data did not meet the standard for approval.

After a day-long meeting that included impassioned testimony from ALS patients, the agency’s expert advisers voted 17-1 with one abstention that the case for NurOwn, a treatment from BrainStorm Cell Therapeutics, was based too heavily on convoluted clinical trial results and compelling but unreliable anecdotal evidence.

“Patients and families need hope, but providing false hope can be ethically problematic,” said panelist Lisa Lee, a bioethicist at Virginia Tech. “False hope is provided when the probability of a positive outcome is overestimated, and I think that seems to be the case here.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Illumina names Agilent executive as new CEO

explore

WSS

Ethical issues complicate the benefits of medical crowdfunding

Illumina names Agilent executive as new CEO

How to protect patients from sexual assault

Trump surgeon general acknowledges mistakes during Covid

Hospitals owned by private equity see complications spike 25%

Covid hospitalizations on the rise, Humana says

Wikipedia

hotspot

focus

Walensky prepares to leave CDC — and Congress — behind

HCA sued by state AG for quality issues at Mission Health

Apple is now the first public company to be valued at $3 trillion

Medicare Advantage beneficiaries sue Humana over algorithm use

How to save PrEP access — and even expand it

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Affirmative action in medical school literally saved lives

Trump surgeon general acknowledges mistakes during Covid

Alkermes shareholders re

SEC charges former device maker CEO with $41 million fraud

knowledge

Keeping primary care docs in field isn't impossible, says AAFP CEO

Why Novartis is changing the name of its research labs

Why health care costs have stayed mostly flat since 2010

How to keep neuroscience’s past racism from being its future

Albert Bourla of Pfizer: worst biopharma CEO of 2023

How to protect patients from sexual assault

explore

hotspot

knowledge

explore